STOCK TITAN

Greenwich LifeSciences Inc - GLSI STOCK NEWS

Welcome to our dedicated news page for Greenwich LifeSciences (Ticker: GLSI), a resource for investors and traders seeking the latest updates and insights on Greenwich LifeSciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Greenwich LifeSciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Greenwich LifeSciences's position in the market.

Rhea-AI Summary
Greenwich LifeSciences, Inc. extends lock-up period for shares owned by directors, officers, and pre-IPO investors until June 30, 2025, restricting sale of common stock. The move aims to maintain stability and confidence in the company during the Phase III clinical trial of GLSI-100, an immunotherapy for breast cancer recurrences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.86%
Tags
none
-
Rhea-AI Summary
Greenwich LifeSciences, Inc. (GLSI) collaborates with GEICAM in Spain to initiate clinical sites for FLAMINGO-01 Phase III trial, targeting breast cancer prevention. GEICAM, a leading research network, will involve 38 hospitals in the study. Spain, with high breast cancer incidence, sees potential in GLSI-100 immunotherapy. Notable experts like Prof. Miguel Martin and Dr. Luis de la Cruz Merino support the innovative approach. CEO Snehal Patel highlights the importance of academic-industry alliances for successful trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.2%
Tags
partnership
-
Rhea-AI Summary
Greenwich LifeSciences, Inc. (GLSI) announces the expansion of its Phase III clinical trial, Flamingo-01, into Europe. The trial, evaluating GLSI-100 for breast cancer prevention, has received formal approval from Spain, France, Germany, Italy, and Poland. The activation of 105 sites across these countries is imminent, with site initiation visits scheduled for March 4, 2024. CEO Snehal Patel expresses excitement about bringing GLSI-100 to a potential patient population of 300 million in Europe.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.48%
Tags
Rhea-AI Summary
Greenwich LifeSciences, Inc. (GLSI) announces the expansion of its Phase III clinical trial, Flamingo-01, into Europe. The European Medicines Agency (EMA) has approved the trial, marking a significant milestone for the Company. CEO Snehal Patel highlights the positive interactions with EMA and the 5 participating countries, indicating progress towards potential EU licensing and US BLA filing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.82%
Tags
none
-
Rhea-AI Summary
Greenwich LifeSciences, Inc. (GLSI) provides an update on Phase III clinical trial Flamingo-01 for GLSI-100, an immunotherapy for breast cancer. No serious adverse events reported. Expansion of clinical sites in the US and Europe. Steering Committee agrees to expand third trial arm. Plans for interim analysis and BLA filing. New patent application filed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.74%
Tags
-
Rhea-AI Summary
Greenwich LifeSciences, Inc. (GLSI) extends lock-up period for shares owned by directors, officers, and pre-IPO investors until December 31, 2024, preventing selling of common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.64%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.54%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.36%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.82%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.35%
Tags
Greenwich LifeSciences Inc

Nasdaq:GLSI

GLSI Rankings

GLSI Stock Data

201.07M
5.81M
52.71%
4.87%
1.09%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Stafford